TPCN2 and Parkinson disease: Elevated TPC2 activity is observed in cells expressing Parkinson’s disease associated mutations in LRRK2 [189], suggesting that attenuation of TPC2 activity (as is the case of TRPML1) might be beneficial in late-onset neurodegenerative diseases.